Table of Contents
New Journal of Science
Volume 2014, Article ID 745808, 13 pages
http://dx.doi.org/10.1155/2014/745808
Review Article

Advances and Prospects in Cancer Immunotherapy

Institute for Tumor Immunology, Ludong University School of Life Sciences, 186 Hongqi Middle Road, Yantai, Shandong 264025, China

Received 9 December 2013; Accepted 11 February 2014; Published 13 March 2014

Academic Editor: Jordi Camps

Copyright © 2014 Juhua Zhou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Cancer immunotherapy is a promising and effective treatment modality for patients with cancers. Cytokine, anticytokine, and antibody therapies appear to be effective in treating various forms of cancer. The human papillomavirus vaccine is protective for cervical cancer, and this discovery has paved the way to the development of cancer vaccines for other forms of virus-associated cancers such as liver cancer and Merkel cell carcinoma. Clinical trials have demonstrated that adoptive cell therapy using tumor-infiltrating lymphocytes can induce tumor regression in approximately 75% of metastatic melanoma patients, suggesting the possibility of using similar technique to effectively treat breast, lung, and renal cancers in the near future. Besides, genetically engineered T cells transduced with genes encoding specific T cell receptors and chimeric antigen receptors have been shown effective in the treatment of cancer patients. These studies suggest that combination therapies are superior choices in cancer immunotherapy for patients.